Stocks · News reference
Filed: 2026-08-04 AccNo: 0001193125-26-331512 Size: 203 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Analysts initiate coverage and change ratings on top stocks like ASND, DOCN, ODTX, MT, and NVCT. See their price targets and views on these stocks.
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.
JP Morgan analyst Brian Cheng maintains Odyssey Therapeutics (NASDAQ:ODTX) with a Overweight and raises the price target from $26 to $29.
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's